Genscript Biotech Corporation
GNNSF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | -29.2% | 34.2% | 22.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 45.8% | 48.8% | 48.6% | 55.3% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $0 | $1 | $1 | $1 |
| Operating Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 1.6% | -49.5% | -69.7% | -72.1% |
| Other Income/Exp. Net | -$0 | $0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$1 |
| Tax Expense | $0 | $0 | -$0 | $0 |
| Net Income | $3 | -$0 | -$0 | -$0 |
| % Margin | 498.2% | -11.4% | -36.3% | -70.2% |
| EPS | 1.4 | -0.045 | -0.11 | -0.18 |
| % Growth | 3,190.5% | 58.8% | 38.9% | – |
| EPS Diluted | 1.36 | -0.045 | -0.11 | -0.18 |
| Weighted Avg Shares Out | 2 | 2 | 2 | 2 |
| Weighted Avg Shares Out Dil | 2 | 2 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 11.8% | -29.6% | -56.7% | -91.1% |